Cost-effectiveness of early versus delayed disease-modifying antirheumatic drugs for psoriatic arthritis
Summary Background Disease-modifying antirheumatic drugs (DMARDs) are standard first-line therapy for psoriatic arthritis (PsA). Observational studies suggest earlier initiation is associated with superior minimal disease activity (MDA) attainment, yet the economic and health implications of treatment timing remain unc...